Cienfuegos, December 21 (RHC)-- The Cuban medication CIMAvax-EGF against advanced lung cancer has begun its final stage of clinical trials in the province of Cienfuegos.
Developed by the Havana-based Molecular Immunology Center, the Cuban vaccine is the first registered therapeutic treatment of its kind that generates antibodies against the patient's epidermal growth factor (EGF).
The antibodies generated by the drug inhibit and stop the proliferation of tumor cells, thus stabilizing the pathology, increasing survival and ostensibly improving the patients' quality of life.
Clinical trial lead researcher Yoana Herrera Leyva said that the aim is to assess the response of patients to high and normal doses of the vaccine, in order to customize the treatment.
Cuban Lung Cancer Vaccine Begins Final Stage of Clinical Trials
Related Articles
Commentaries
MAKE A COMMENT
All fields requiredMore Views
- UN special rapporteur warns Israel's crimes in Gaza could keep International Court of Justice busy at The Hague for 50 years
- Arab countries at United Nations declare full support for new UN Security Council resolution that calls for permanent ceasefire in Gaza
- Israeli forces raped, tortured and executed Palestinian women at Al-Shifa Hospital
- International Labor Organization says profits from forced labor at nearly one-quarter of a trillion dollars
- Cuba condemns terrorist act in the Moscow region